Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

Principal Investigator: Gandhi, Shipra

Aromatherapy: An Integrative Option for Symptom Management in Cancer Care

Principal Investigator: Rokitka, Denise A

A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

(ACNS1831) A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Principal Investigator: Barth, Matthew J

(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Principal Investigator: Puzanov, Igor

Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia

Principal Investigator: Kelly, Kara M

Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors: A Feasibility Pilot Trial

Principal Investigator: O'Connor, Tracey L

AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line…

Principal Investigator: Kelly, Kara M

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomization Trial

Principal Investigator: Levine, Ellis G

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Principal Investigator: George, Saby

(NRG-GY006) A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal…

Principal Investigator: Lele, Shashikant B

Impact of Menthol Delivery Methods on Smoker Sensory Perceptions

Principal Investigator: O'Connor, Richard J

(ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE

Principal Investigator: Odunsi, Adekunle O

A Multicenter Phase 2, Adaptive, Open-Label Trial of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or…

Principal Investigator: Puzanov, Igor

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Principal Investigator: George, Saby

DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Principal Investigator: Kelly, Kara M

A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS.

Principal Investigator: Balderman, Sophia R

A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia

Principal Investigator: Chen, George L

A Phase 1/2, Multicenter, Open-Label, Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Principal Investigator: Wang, Eunice S

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Principal Investigator: Iyer, Renuka V

ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Principal Investigator: Twist, Clare J

A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) given with Adjuvant Poly-ICLC in Conjunction with 5-Aza-2'deoxycytidine (Decitabine) and Nivolumab in Patients with MDS or Low Blast Count AML

Principal Investigator: Griffiths, Elizabeth A

RCT of Online Mindfulness-Based Stress Reduction for Metastatic Breast Cancer Patients

Principal Investigator: Hydeman, Jennifer A

Molecular Analysis for Therapy Choice MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase 2 Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations

Principal Investigator: Levine, Ellis G